Publications en collaboration avec des chercheurs de Hospital Universitario Virgen del Rocío (58)

2023

  1. Combination Therapy of Chemotherapy or Radiotherapy and the Neurokinin-1 Receptor Antagonist Aprepitant: A New Antitumor Strategy?

    Current Medicinal Chemistry, Vol. 30, Núm. 16, pp. 1798-1812

  2. Mobile Health Requirements for the Occupational Health Assessment of Health Care Professionals: Delphi Study

    JMIR Formative Research, Vol. 7

  3. The Repurposing of Non-Peptide Neurokinin-1 Receptor Antagonists as Antitumor Drugs: An Urgent Challenge for Aprepitant

    International Journal of Molecular Sciences, Vol. 24, Núm. 21

2022

  1. Involvement of the Substance P/Neurokinin-1 Receptor System in Cancer

    Cancers

  2. The Neurokinin-1 Receptor Is Essential for the Viability of Human Glioma Cells: A Possible Target for Treating Glioblastoma

    BioMed research international, Vol. 2022, pp. 6291504

  3. Why Use Aprepitant Only as a Cough Suppressant in Lung Cancer When at Higher Doses it Could Also Exert an Antitumor Action?

    Archivos de Bronconeumologia

2020

  1. Involvement of the substance p/neurokinin-1 receptor system in oral pain and inflammation

    Journal of Biological Regulators and Homeostatic Agents

  2. Neurokinin receptor antagonism: a patent review (2014-present)

    Expert Opinion on Therapeutic Patents, Vol. 30, Núm. 7, pp. 527-539

  3. The neurokinin-1 receptor antagonist aprepitant, a new drug for the treatment of hematological malignancies: Focus on acute myeloid leukemia

    Journal of Clinical Medicine, Vol. 9, Núm. 6

  4. The neurokinin-1 receptor antagonist aprepitant: An intelligent bullet against cancer?

    Cancers, Vol. 12, Núm. 9, pp. 1-22

  5. The substance P and neurokinin-1 receptor system in human thyroid cancer: An immunohistochemical study

    European Journal of Histochemistry, Vol. 64, Núm. 2

  6. Triple Negative Breast Cancer: How Neurokinin-1 Receptor Antagonists Could Be Used as a New Therapeutic Approach

    Mini reviews in medicinal chemistry, Vol. 20, Núm. 5, pp. 408-417

2019

  1. Antipruritic vs. Antitumour action of aprepitant: A question of dose

    Acta Dermato-Venereologica

  2. Glioma and neurokinin-1 receptor antagonists: A new therapeutic approach

    Anti-Cancer Agents in Medicinal Chemistry, Vol. 19, Núm. 1, pp. 92-100

  3. Neurokinin-1 receptor antagonist aprepitant and radiotherapy, a successful combination therapy in a patient with lung cancer: A case report

    Molecular and Clinical Oncology, Vol. 11, Núm. 1, pp. 50-54

  4. Neurokinin-1 receptor antagonists against hepatoblastoma

    Cancers, Vol. 11, Núm. 9

  5. Neurokinin-1 receptor antagonists as anticancer drugs

    Letters in Drug Design and Discovery, Vol. 16, Núm. 10, pp. 1110-1129

  6. PLA2G6-associated neurodegeneration: New insights into brain abnormalities and disease progression

    Parkinsonism and Related Disorders, Vol. 61, pp. 179-186

  7. The involvement of the substance P/neurokinin 1 receptor system in viral infection: Focus on the gp120 fusion protein and homologous dipeptide domains

    Acta Virologica, Vol. 63, Núm. 3, pp. 253-260

2018

  1. Substance P

    Encyclopedia of Endocrine Diseases (Elsevier), pp. 571-578